Fingolimod (Gilenya, TDI 132)

Fingolimod may slow the degeneration of the motor nerves by reducing neuroinflammation. A sphigosine 1 phosphate receptor agonist, fingolimod blocks the infiltration of T cells into the nervous system by reducing their circulation in the blood. Fingolimod, marketed by Novartis under the name Gilenya, is FDA-approved to treat certain forms of multiple sclerosis.

Status

Type:	Small Molecule
Stage:	Completed
Status:	Inactive
Sponsor:	ALS Therapy Development Institute

TDI Says:

Preclinical testing of Gilenya showed a positive trend on ALS progression and survival. Therefore, we decided to advance this drug into a phase II clinical trial. This trial will not measure efficacy of Gilenya. Rather, it is designed to determine whether Gilenya can be given to ALS patients safely. Results and any next steps will be announced when determined.

Learn More

Gilenya, giving ALS the fingo?

A phase IIA trial asks whether Gilenya might have the potential to slow ALS by reducing T cell-mediated inflammation.
NEALS 2013: ALS, North by Northeast

Clinicians weigh in on the latest potential treatments for ALS being tested in clinics today.

Clinical Trials

Why might fingolimod be helpful for ALS?

The scientific rationale for fingolimod in ALS.
Frequently Asked Questions

ALS TDI answers key questions about the phase IIA clinical trial
Gilenya in ALS

Learn more about the phase IIA clinical trial - including eligibility criteria and site locations.